Deborah D. Brown - Concepedia

Author

Deborah D. Brown

Also Known As

BROWN, D, D. Brown, Deborah Brown, Deborah D. Brown, Deborah D. Brown, Dhanjai Brown

Publications

855

Citations

H-Index

Concepts

All Affiliations

Deborah D. Brown is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in vaccination, vaccine safety, and immunology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	25
2	Immunology	1	1	25
3	Covid-19	1	1	25
4	Vaccination	1	1	25
5	Vaccine Efficacy	1	1	25

Deborah D. Brown

Publications

808

Citations

H-Index

Page 1

	Year	Citations
Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy, Annals of Internal Medicine	2015	514
Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy Adults Frances Priddy, Deborah D. Brown, James G. Kublin, Clinical Infectious Diseases	2008	238
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, EBioMedicine VaccinationVaccine SafetyPhase 1/2Vaccine TargetImmunology	2022	25
HIV Seroconversion without Infection after Receipt of Adenovirus‐Vectored HIV Type 1 Vaccine Erin Quirk, Robin Mogg, Deborah D. Brown, Clinical Infectious Diseases	2008	20
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study Tarik Asselah, Stanislas Pol, Christophe Hézode, Liver International	2019	11

Page 1